Jan van de Winkel
President and CEO at Genmab
Meet Jan van de Winkel
After co-founding Genmab and serving as President, Research and Development and Chief Scientific Officer, van de Winkel was appointed President and Chief Executive Officer in 2010. Under his leadership, Genmab has created three antibody medicines that all received Breakthrough Therapy Designations from the FDA and are now commercialized by partners: Darzalex, a backbone therapy for multiple myeloma, commercialized by Janssen; Kesimpta by Novartis; and Tepezza by Horizon Therapeutics.
“We believe that partnerships and collaborations are foundational to accelerate innovation and bring medicines to patients as quickly as possible. It takes an innovation ecosystem with partnerships between biotech and big pharma, academia, research institutes, data sciences companies or medical electronics companies to catalyze break-through innovation.”